Mean Kinetic Relative Humidity: A New Concept for Assessing the Impact of Variable Relative Humidity on Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mean Kinetic Relative Humidity: A New Concept for Assessing the Impact of Variable Relative Humidity on Pharmaceuticals
This article introduces the concept of "mean kinetic relative humidity" (MKRH) for evaluating the impact of humidity variability on the stability of solid-state pharmaceuticals analogously to the way mean kinetic temperature (MKT) is used for assessing the impact of temperature variability.


Pharmaceutical Technology
Volume 36, Issue 11, pp. 52-57

Conclusion

An equation for the calculation of MKRH is based upon the humidity-corrected Arrhenius equation, which has been shown to be applicable to a wide variety of solid-state pharmaceutical products and active substances. The calculation of the MKRH requires a moisture sensitivity parameter, B, to be known, analogously to the way Ea is required for the calculation of MKT. In many situations, such as those involving chemical degradation, the use of MKRH is more appropriate than the use of the arithmetic mean relative humidity, in much the same way that MKT is more appropriate than the use of arithmetic mean temperature.

It is relatively simple to calculate the MKRH for constant temperature situations or to calculate the MKT for constant humidity conditions using established methods, such as those described in USP <1150> (4). In situations that have both variable temperatures and humidity conditions, it may be necessary to use a combined temperature and relative humidity calculation as described above, which provides a continuum of constant temperature and constant relative humidity combinations that would age the product to the same degree as the set of variable temperature and variable relative humidity conditions. However, in most situations, this combined calculation is not likely to be necessary, because either the relative humidity can be considered to be effectively constant (e.g., when considering packaged products over short time periods, such as with temperature excursions that occur during the distribution of products), or the temperature can be considered constant (e.g., during stability testing of packaged products in which the relative humidity inside the packaging changes dynamically over time and testing occurs at specific conditions, such as 25 C/60% RH or 40 C/75% RH). Despite its limitations and its apparent complexity, the MKRH approach should prove useful in a number of pharmaceutically relevant situations, as has the analogous concept of MKT.

Acknowledgments

The author would like to thank Ken Waterman for his inspirational scientific guidance and Bill Porter for stimulating technical discussions. The author would also like to thank Tim Lukas, Bruno Hancock, and Pierre Barratt for their useful comments and feedback.

Garry Scrivens, PhD, is in Pharmaceutical Sciences at Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, UK, CT13 9NJ, tel. + 44 0 1304 649578,
.

Submitted: Mar. 2, 2012; Accepted Mar. 28, 2012.

References

1. ICH, Q1A(R2), Stability Testing of New Drug Substances and Products, Step 4 version (2003).

2. J. D. Haynes, J. Pharm. Sci., 60 (6), 927–929 (1971).

3. W. Grimm, Drug Dev. Ind. Pharm., 24 (4), 313–325 (1998).

4. USP 34–NF 29 General Chapter <1150>, "Pharmaceutical Stability," pp. 693–694.

5. M. Zahn, "Global Stability Practices," in Handbook of Stability Testing in Pharmaceutical Development, K. Huynh-Ba, Ed. (Springer Science and Business, New York, NY, 2009), pp. 43–91.

6. R. H. Seevers et al., Pharma. Outsourcing, 10 (3), 30–35 (2009).

7. B. Kommanaboyina and C. T. Rhodes, Drug Dev. Ind. Pharm., 25 (12), 1301–1306 (1999).

8. D. Genton and U. W. Kesselring, J. Pharm. Sci., 66 (5), 676–680 (1977).

9. K. C. Waterman and R. C. Adami, Int. J. Pharm., 293 (1–2), 101–125 (2005).

10. K.C. Waterman, et al., Pharm. Research, 24 (4), 780–790 (2007).

11. K.C. Waterman and S. T. Colgan, Regulatory Rapporteur, 5 (7), 9–14 (2008).

12. K. C. Waterman, "Understanding and Predicting Pharmaceutical Product Shelf-Life," in Handbook of Stability Testing in Pharmaceutical Development, K. Huynh-Ba, Ed. (Springer Science and Business, New York, NY, 2009), pp. 115–135.

13. W. Grimm and G. Schepky, Stabilitatsprufung in der Pharmazie, Theorie und Praxis, (Editio Cantor Verlag, Aulendorf, 1980).

14. L. Kennon, J. Pharm. Sci., 53 (8), 815–81 (1964).

15. K. C. Waterman and B. C. MacDonald, J. Pharm. Sci., 99 (11), 4437–4452 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here